2-Furylethylamine (2-FEA or FEA) is a drug of the arylalkylamine family related to the substituted phenethylamines such as β-phenethylamine (PEA) and amphetamine. It is known to have similar pressor effects as amphetamine and strong constricting effects on the uterus in animals. The psychoactive effects of FEA in humans are unknown.
Derivatives of FEA include α-Me-FEA (furylisopropylamine) and α,N-Me-FEA, among others. α-Me-FEA was less several-fold potent than amphetamine in animals and showed limited effects in humans. Analogues of FEA, besides β-phenethylamine (PEA) and amphetamine (α-Me-PEA), include TH-FEA, α-Me-TH-FEA, ThEA, thiopropamine (α-Me-ThEA), 3-ThEA, 2-(2-pyrrolyl)ethylamine (NEA), and α-Me-NEA, among others. Some of them are known to be active.
FEA was first synthesized by 1920. FEA and analogues were studied by Gordon Alles and colleagues, who discovered its pressor effects. FEA is not a controlled substance in the United States as of 2011.
Phenethylamine
Amphetamine
Thiopropamine
Safety at a Glance
High Risk- France: As of december 2024, 2-FEA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
- New Zealand: 2-FEA is
- Toxicity: The toxicity and long-term health effects of recreational 2-FEA use do not seem to have been studied in any scientifi...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Cocaine (+5 more)
- Overdose risk: Stimulant overdose from 2-FEA is a medical emergency primarily involving cardiovascular and neuro...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
Duration
insufflated
Total: 1 hrs – 2.5 hrsHow It Feels
The onset of 2-FEA arrives within thirty to forty-five minutes as a dual current: stimulation and warmth rising together like two braided streams. A gentle rush of energy builds in the chest, but alongside it there is something softer, a hint of emotional openness that distinguishes this compound from its purely stimulant relatives. The heart rate picks up, the body feels lighter, and there is a growing desire not just to act but to connect.
As the experience develops over the next hour, the empathogenic qualities become more pronounced. Social warmth suffuses conversations with an easeful intimacy. Others seem more interesting, their words carrying more weight, their presence more welcome. Touch sensitivity increases subtly, and there is a mild but unmistakable expansion of emotional bandwidth. The stimulant component keeps the mind clear and the body energized, preventing the dreamy heaviness that can accompany more serotonergic compounds. Music takes on added richness and emotional resonance, and physical movement feels fluid and pleasurable.
At the peak, roughly two hours in, 2-FEA occupies a middle ground between stimulant productivity and entactogenic closeness. The mood is elevated without being manic, empathetic without being overwhelming. The jaw clenches with moderate insistence, the pupils dilate, and body temperature rises slightly. Appetite is suppressed and there is a fine, buzzing energy in the muscles that encourages movement. The overall character is sociable and warm, well-suited to extended conversations, dancing, or any activity where energized connection is valued.
The decline begins around four to five hours in, and the landing is relatively forgiving. The empathogenic glow fades first, leaving behind a clean residual stimulation that tapers over another hour or two. There may be some tiredness as the serotonergic component recedes, and a mild emotional flatness in the hours that follow. Sleep can be delayed if the dose was taken late, and the next day may carry a faint weariness, though nothing approaching the depleted aftermath of stronger entactogens. The total duration of five to seven hours makes 2-FEA a manageable experience with a character that splits the difference between work and warmth.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(25)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Bronchodilation— Bronchodilation is the widening of the bronchial airways in the lungs, reducing resistance to airflo...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stamina enhancement— Stamina enhancement is an increase in one's ability to sustain physical and mental exertion over ext...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temporary erectile dysfunction— Temporary erectile dysfunction is the substance-induced inability to achieve or sustain a penile ere...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(3)
- Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
Cognitive(27)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Emotion suppression— A blunting or flattening of emotional experience in which feelings become muted, distant, or seeming...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Focus enhancement— An enhanced ability to direct and sustain attention on a single task or stimulus with unusual clarit...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Thought organization— Enhanced ability to structure, categorize, and systematize thoughts and ideas, common with low-dose ...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
2-FEA has not yet been formally studied to the same extent as traditional amphetamines. Currently, it is assumed that it most likely acts primarily as a triple reuptake inhibitor, and that it releases the neurotransmitters: serotonin, dopamine, and norepinephrine. 2-FEA likely creates it effects by acting as a releasing agent of said neurotransmitters and/or by binding to- and partially blocking the transporter proteins that normally clear substances from the synaptic cleft, after they have fulfilled their function of conducting a neural impulse.
The effects of 2-FEA appear to be very subtle and difficult to characterize. Some reports suggest it is relatively mild and free of side effects in a similar fashion to 2-FA, while others note an increase in physical side effects or serotonergic activity reminiscent of 3-FEA.
The toxicity and long-term health effects of recreational 2-exact toxic dosage is unknown. This is because 2-FEA has a very limited history of human usage.
Anecdotal reports from those who have tried 2-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself or using it sparingly (but nothing can be completely guaranteed).
It is strongly recommended that one use harm reduction practices when using this substance.
As with other stimulants, the chronic use of 2-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 2-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). 2-FEA presents cross-tolerance with Cross-all dopaminergic stimulants, meaning that after the consumption of 2-FEA all stimulants will have a reduced effect.
Detection Methods
Standard Drug Panel Inclusion
2-FEA (2-Fluoroethamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.
Urine Detection
Due to the structural similarity to amphetamine, 2-FEA (2-Fluoroethamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 2-FEA (2-Fluoroethamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 2-FEA (2-Fluoroethamphetamine) unless the specific assay has unusually broad cross-reactivity.
Blood and Saliva Detection
2-FEA (2-Fluoroethamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.
Hair Follicle Detection
Hair follicle analysis can theoretically detect 2-FEA (2-Fluoroethamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 2-FEA (2-Fluoroethamphetamine).
Confirmatory Testing
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 2-FEA (2-Fluoroethamphetamine). These techniques can distinguish 2-FEA (2-Fluoroethamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 2-FEA (2-Fluoroethamphetamine) must be available to the testing laboratory for positive identification.
Reagent Testing
Marquis reagent produces no reaction or a faint orange-brown color with 2-FEA (2-Fluoroethamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 2-FEA (2-Fluoroethamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Cocaine | Dangerous | — |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Dangerous | — |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
2-FEA is part of the stimulant class of psychoactive substances, which has a long and complex history spanning medical, military, occupational, and recreational use.
The modern history of stimulants begins with the isolation of ephedrine from traditional Chinese medicine in the 1880s, followed by the synthesis of amphetamine in 1887 and methamphetamine in 1893. Throughout the 20th century, stimulants were widely prescribed for conditions ranging from nasal congestion to depression, and were extensively used by militaries during World War II and the Korean War.
The recognition of abuse potential and adverse health effects led to increasing regulation from the 1960s onward, though stimulant medications remain among the most commonly prescribed treatments for ADHD and narcolepsy.
2-FEA exists within this broader context of stimulant pharmacology, with its specific history shaped by its date of development, clinical applications (if any), legal status, and pattern of use within different communities.
Harm Reduction
As with other stimulants, the chronic use of 2-moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 2-develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). 2-FEA presents cross-tolerance with Cross-all dopaminergic stimulants, meaning that after the consumption of 2-FEA all stimulants will have a reduced effect.
Toxicity & Safety
The toxicity and long-term health effects of recreational 2-FEA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-FEA has a very limited history of human usage.
Anecdotal reports from those who have tried 2-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself or using it sparingly (but nothing can be completely guaranteed).
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
As with other stimulants, the chronic use of 2-FEA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 2-FEA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 2-FEA presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 2-FEA all stimulants will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Stimulants - 2-FEA can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with 2-FEA should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
Stimulants - 2-FEA may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
Tramadol - Tramadol is known to lower the seizure threshold and combinations with stimulants may further increase this risk.
MDMA - The neurotoxic effects of MDMA may be increased when combined with amphetamines.
MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.
Cocaine - This combination may increase strain on the heart.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from 2-FEA is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
2-FEA is currently a gray area compound within all parts of the world, meaning its regulation lies in a legal gray area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Canada: 2-FEA would be considered Schedule I as it is an analogue of Amphetamine.
France: As of december 2024, 2-FEA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
Germany: 2-FEA is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
New Zealand: 2-FEA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.
The Netherlands:** 2-FEA is a controlled substance as of July 1, 2025.
Switzerland: 2-FEA can be considered a controlled substance as a defined derivative of a-methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.
United Kingdom: 2-FEA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.
Responsible use
Research chemical
Stimulant
Substituted amphetamine
3-FEA (Isomer Design)
Experience Reports (1)
Tips (7)
If you snort 2-FEA, use a clean straw (never shared), crush the powder as finely as possible, alternate nostrils, and rinse with saline spray after your session. Chronic insufflation damages nasal tissue and septum.
Monitor your heart rate and blood pressure when using 2-FEA. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
Have a landing plan for the 2-FEA comedown. Prepare food, melatonin or magnesium, and a comfortable environment in advance. Avoid using depressants to manage the comedown as this creates polydrug dependency patterns.
2-FEA can cause unpleasant side effects including dizziness, feeling cold, anxiety, and nausea that are not typically seen with the closely related 3-FEA. Approach this compound with more caution than other fluorinated amphetamines.
As a very new research chemical with minimal human data, always start with an allergy test followed by a very low dose. Multiple users have reported uncomfortable physical side effects that differ from the well-tolerated 3-FEA profile.
2-FEA provides mild stimulation that fades quickly, making it underwhelming compared to 3-FEA. Its primary value may be as a functional stimulant rather than a recreational one. Some find it pairs well with 3-FEA to balance out the latter's rolly effects.
Community Discussions (2)
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- 2-FEA - TripSit Factsheet
TripSit factsheet for 2-FEA
tripsit - 2-FEA - Wikipedia
Wikipedia article on 2-FEA
wikipedia